Meet the Board

The Föreningen ATMP Sweden (fATMP Sweden) board is committed to supporting the development of ATMPs, towards better care for patients in need. The board represents expertise across the ATMP pipeline, including industry, clinical research, and healthcare and share a vision to support and continue to build communication and collaboration between ATMP stakeholders. The board believes in the value of the established ATMP Sweden communication and coordination platforms and aim to not only strengthen the existing network but to improve development efficiency through identifying and closing gaps in the development pipeline.

Elias Uhlin – Chair

Director, Lund Stem Cell Center Pre-GMP Facility

Elias Uhlin is the Director of the Pre-GMP Facility at Lund Stem Cell Center, where he has established a cutting-edge cell and gene therapy process development facility. His expertise lies in fostering collaborations between academia, healthcare, and industry to advance ATMPs from research ideas to clinical trials and commercial viability.

With experience from CCRM in Toronto and Karolinska Institutet, Elias has led projects on iPSC-derived therapies and played a key role in developing Sweden’s ATMP ecosystem. His commitment to strengthening Sweden’s position in the global ATMP landscape is evident through his work in streamlining development processes, regulatory strategies, and clinical translation.

As Head Chair of ATMP Sweden, Elias aims to enhance national coordination, improve patient access to ATMPs, and position Sweden as a leader in the field by showcasing groundbreaking innovations and fostering collaboration with key stakeholders.

Ellen Andreasson

CEO & Co-founder, Envue Technologies

Ellen Andreasson is the CEO and Co-founder of Envue Technologies, a Chalmers spinout dedicated to accelerating nanomedicine development through a patented bioanalytical tool. With an M.Sc. in Biotechnology, her expertise spans entrepreneurship, executive management, and business strategy, with a strong focus on advancing life science innovation.

Her experience includes forging strategic partnerships both nationally and internationally to support the development of transformative therapies. She is driven by a passion for purpose-led, high-impact initiatives that push the boundaries of medicine and improve patient outcomes.

Through her role on the ATMP Sweden board, Ellen is committed to strengthening Sweden’s position in the global life science landscape and contributing to the continued development of cutting-edge therapies.

Michael Delahaye

Senior Director of Technical Operations, CCRM Nordic

Michael Delahaye is Senior Director of Technical Operations at CCRM Nordic, bringing over 15 years of industrial experience in the cell and gene therapy sector. His expertise lies in developing scalable and robust manufacturing processes, utilizing high-resolution characterization tools to support the production of advanced therapies.

Previously, he held roles in Biopharmaceuticals R&D at AstraZeneca, led the Viral Vector Industrialization team at the Cell and Gene Therapy Catapult, and completed an EngD at University College London with multiple industrial collaborations. He also serves as an adjunct Associate Professor at Linköping University and is a Director of the ATMP Manufacturing Community (AMC) in the UK.

Since relocating to Sweden in 2021, Michael has been inspired by the country’s collaborative ATMP ecosystem. On the ATMP Sweden board, he aims to support knowledge sharing, industry-academic partnerships, and the integration of Swedish innovations into the global ATMP community.

Kerstin Sollerbrant

Senior expert, research at The Swedish Childhood Cancer Fund

Kerstin Sollerbrant, Senior Expert at The Swedish Childhood Cancer Fund, associate professor at Karolinska Institute, and patient representative in EMA’s Committee for Advanced Therapies, emphasizes the significance of ATMPs for “difficult-to-treat” diseases, including many cancers, rare, and genetic diseases.

The Swedish Childhood Cancer Fund acknowledges the importance of this field and the need to elevate the patient’s perspective in medicine development. Through ATMP Sweden, Kerstin aims to contribute to faster access to safe and effective innovative therapies for patients who need them the most.

Alexandra Karström

Head of Cell & Tissue Therapy at Plastic Surgery, Uppsala University Hospital

With a career spanning from the Karolinska Institute to Uppsala University Hospital, Alexandra Karström heads the Tissue Establishment at the Department for Plastic and Maxillofacial Surgery. Her work includes the production of autologous keratinocytes, processing allogeneic donor skin, and autologous partial skin for burn patients, under the Swedish Medical Products Agency’s approval.

Alexandra’s extensive experience in manufacturing cell products and ATMPs for clinical use is complemented by her national roles, including chairing the National Expert Group for Cell and ATMP Therapies (VOG Cell), and being a board member of the National Research School for ATMP and CAMP. Her contributions to quality certifications and accreditations in healthcare further enhance her impact on ATMP Sweden.

Jenny Nelander

Researcher in Developmental & Regenerative Neurobiology, Lund University

Jenny Nelander is an assistant researcher in the Developmental and Regenerative Neurobiology group at Lund University, as well as LU-ATMP and the Lund Stem Cell Center Pre-GMP Facility. Her career has focused on the translational work necessary to bring hESC-derived dopaminergic neurons to clinical applications.

A key contributor to the STEM-PD trial, Sweden’s first-in-human ATMP trial for Parkinson’s disease, Jenny has extensive experience in preclinical research, clinical trial development, and regulatory aspects of ATMP manufacturing. Her expertise spans the critical steps needed to move cell-based therapies from the lab to patients.

As a board member of ATMP Sweden, Jenny is committed to supporting Sweden’s leadership in ATMP development by fostering collaboration, optimizing clinical translation processes, and ensuring patient access to cutting-edge therapies.

Anders Lindahl

Senior professor MD, PhD

Anders Lindahl brings extensive expertise in ATMP, particularly through his pioneering work with autologous cartilage cell transplants for treating secondary osteoarthritis since 1994. This technique has been adopted globally, benefiting over 50,000 patients.

Anders’s contribution to ATMP Sweden includes his profound knowledge in medical, cell culture, technical, and regulatory domains. His international network and ability to facilitate agreements will further strengthen the organization’s initiatives.

Lindsay Davies

CEO and Founder CellTherEx Consulting AB and CSO NextCell Pharma AB, co-founder QVance AB, ISCT European Regional Secretary

Lindsay Davies has a strong background in translational stem and stromal cell biology research, recently transitioning into industry as Chief Scientific Officer and Business Developer at NextCell Pharma AB. She also leads CellTherEx Consulting, where she focuses on advancing novel therapies into clinical applications.

Maintaining close academic ties, Lindsay is affiliated with Karolinska Institutet, where she continues research on oral progenitor cell biology, mesenchymal stromal cell therapy, and their potential in treating immune-mediated disorders. She is also actively involved in international ATMP initiatives, including serving as Regional Secretary for the International Society of Cell and Gene Therapy.

Through her role on the ATMP Sweden board, Lindsay aims to enhance collaboration, drive innovation, and improve accessibility to advanced therapies, ensuring Sweden remains at the forefront of ATMP development.

Björn Skölving

General Manager Nordics & Benelux, Orchard Therapeutics – U.S.

Björn Skölving is a seasoned pharmaceutical industry professional with over 20 years of experience in both medical and commercial roles. For the past seven years, he has focused specifically on ATMPs, playing a key role in launching Sweden’s first EMA-approved CAR-T therapy and multiple gene therapies for rare diseases across the Nordics.

His expertise includes enabling the operational readiness of treatment centers, addressing medical and regulatory challenges, and navigating cross-border healthcare to expand patient access. He has a deep understanding of market access and the complexities involved in bringing ATMPs to patients.

As a board member of ATMP Sweden, Björn brings valuable insights into commercial and medical strategies for ATMP adoption. His goal is to help Sweden overcome barriers in ATMP development and implementation, contributing to the vision of making Sweden a world leader in ATMPs by 2030.

Margareth Jorvid (Auditor)

Margareth Jorvid has over 30 years of experience in Regulatory Affairs, having worked at the Swedish Medical Products Agency (MPA) and within major pharmaceutical and biotech companies such as Roussel Nordiska, Hoechst Marion Roussel, and Neopharma.

Since 2006, she has been a regulatory affairs and quality assurance consultant specializing in pharmaceuticals, ATMPs, medical devices, and combination products through her company, Methra Uppsala AB, part of the LSM group. Margareth holds a MSc Pharm from Uppsala University, an MBA from Stockholm School of Economics, and an MSc MTRA from Cranfield University in the UK.

Through her work with ATMP Sweden, Margareth brings critical regulatory expertise to support the development and approval of innovative therapies. As a board member, she remains dedicated to strengthening Sweden’s ATMP landscape by ensuring effective regulatory pathways and facilitating industry growth.